Pulmonology Medical News about lung cancer;bone metatasis;zoledronic acid therapy;survival

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis
International Journal of Cancer, 06/16/09

Zarogoulidis K et al. - In a study to examine the clinical impact of zoledronic acid (ZOL) with a focus on the survival, time to progression, and pain effect in lung cancer pts with bone metastases, it was concluded that the addition of ZOL increases overall survival in lung cancer pts with bone metastases. The longer the period of receiving ZOL, the better effect on survival and time to progression.

Methods

Lung cancer pts (n = 144, Stage IV) with evidence of metastasis bone scan were included.
87 of 144 experienced bone pain and received ZOL, 4 mg i.v. every 21 days (Group A), whereas the other 57 pts received no ZOL (Group B).
All pts were treated with a combination chemotherapy that consisted of docetaxel 100 mg/m2 and carboplatin AUC = 6.

Results

Group A had a statistically significant longer survival when compared to Group B.
A statistically significant positive correlation was found between number of cycles of therapy with ZOL and total patient survival and time to progression.
Pain effect of ZOL had no significant difference between the 2 groups of pts.
Urine N-telopeptide of type I collagen (NTx) levels decreased in pts with NTx ≤29 nM BCE/mM creatinine at baseline after treatment with ZOL.

<< Previous
Subdivision of the T1 Size Descriptor For Stage I Non-Small Cell...

Next >>
Approach to the diagnosis and management of suspected...